05:59 PM EDT, 10/16/2025 (MT Newswires) -- Disc Medicine ( IRON ) said late Thursday it has received Commissioner's National Priority Voucher, meant to expedite drug review process, from the US Food and Drug Administration for its drug candidate bitopertin.

The company is seeking an accelerated approval of bitopertin for the treatment of erythropoietic protoporphyria, a rare and potentially life-threatening disease that causes severe reactions when patients are exposed to sunlight.

The program is aimed to reduce the drug application review process to one to two months, the company added.

Shares of Disc Medicine ( IRON ) were up 19% in after-hours trading.